A prospective, multicenter, clinical study to evaluate the safety, pharmacokinetics, and efficacy of bleed outcomes, with HemoRel-A® in severe hemophilia A patients
A prospective, multicenter, clinical study to evaluate the safety, pharmacokinetics, and efficacy of bleed outcomes, with HemoRel-A® in severe hemophilia A patients
Purpose: To evaluate efficacy for an on-demand treatment of acute bleeding events, pharmacokinetics, safety, and tolerability of HemoRel-A® in severe hemophilia A. Methods: A total of 44 male subjects with severe hemophilia A with an annualized bleed rate of 12 while on-demand treatment with factor VIII (FVIII) were enrolled in the study and received HemoRel-A® for bleed treatment. The efficacy of HemoRel-A® was evaluated based on a four-point scale (excellent, good, moderate, or none). Six-point pharmacokinetic (PK) assessment was performed following a single dose of 50 IU/kg in 12 subjects after a 7-day wash-out period. Safety evaluations were performed at each visit and inhibitor testing was performed in all patients at screening and end of study. Results: Forty-four male subjects received at least a single dose of the study medication and were included in the intent-to-treat (ITT) analysis and safety outcome. In 23 (7.52%) out of the 306 bleeding events, HemoRel-A® efficacy was rated as excellent, in 272 (88.89 %) bleeds it was rated as good, and in 11 (3.68%) bleeding events it was rated as moderate. No failure of efficacy was noted in any of the bleeding events. Thus overall out of 306 bleeding events, 295 (96.41%) showed excellent or good efficacy. Pharmacokinetic assessment based on plasma FVIII activity measured by the chromogenic assay in 12 patients showed comparative results similar to FVIII preparations. A total of 12 adverse events (AEs) were reported in this study. There was no inhibitor development in this previously treated patients (PTP) cohort. Conclusion: HemoRel-A® was established to be efficacious and safe in the treatment of acute bleeding events in subjects with severe hemophilia A.
72-75
Mewada, Mayur
68857578-9cd6-408e-81e5-c2e6fc0bdd31
Sanyal, Subhaprakash
25aa84a8-fdff-4d54-b4ba-b92ab2800a2a
Rangarajan, Savita
9a5e4c7e-55ba-4a3a-b5f6-f1e269d927c3
Apsangikar, Prasad
c25e2bd0-650d-45aa-8088-bd8f1bcdcb9b
Yadav, Ajay Kumar
6eac9c5e-23a0-4fac-be03-7b3662c5d681
Naik, Manoj
d1294e61-b246-4bbd-a630-a4193d445c77
Nair, Santosh
493bfce1-caab-4529-bd7b-5dca5a41e82a
1 July 2022
Mewada, Mayur
68857578-9cd6-408e-81e5-c2e6fc0bdd31
Sanyal, Subhaprakash
25aa84a8-fdff-4d54-b4ba-b92ab2800a2a
Rangarajan, Savita
9a5e4c7e-55ba-4a3a-b5f6-f1e269d927c3
Apsangikar, Prasad
c25e2bd0-650d-45aa-8088-bd8f1bcdcb9b
Yadav, Ajay Kumar
6eac9c5e-23a0-4fac-be03-7b3662c5d681
Naik, Manoj
d1294e61-b246-4bbd-a630-a4193d445c77
Nair, Santosh
493bfce1-caab-4529-bd7b-5dca5a41e82a
Mewada, Mayur, Sanyal, Subhaprakash, Rangarajan, Savita, Apsangikar, Prasad, Yadav, Ajay Kumar, Naik, Manoj and Nair, Santosh
(2022)
A prospective, multicenter, clinical study to evaluate the safety, pharmacokinetics, and efficacy of bleed outcomes, with HemoRel-A® in severe hemophilia A patients.
The Journal of the Association of Physicians of India, 70 (7), , [ISSN 0004-5772].
(doi:10.5005/japi-11001-0039).
Abstract
Purpose: To evaluate efficacy for an on-demand treatment of acute bleeding events, pharmacokinetics, safety, and tolerability of HemoRel-A® in severe hemophilia A. Methods: A total of 44 male subjects with severe hemophilia A with an annualized bleed rate of 12 while on-demand treatment with factor VIII (FVIII) were enrolled in the study and received HemoRel-A® for bleed treatment. The efficacy of HemoRel-A® was evaluated based on a four-point scale (excellent, good, moderate, or none). Six-point pharmacokinetic (PK) assessment was performed following a single dose of 50 IU/kg in 12 subjects after a 7-day wash-out period. Safety evaluations were performed at each visit and inhibitor testing was performed in all patients at screening and end of study. Results: Forty-four male subjects received at least a single dose of the study medication and were included in the intent-to-treat (ITT) analysis and safety outcome. In 23 (7.52%) out of the 306 bleeding events, HemoRel-A® efficacy was rated as excellent, in 272 (88.89 %) bleeds it was rated as good, and in 11 (3.68%) bleeding events it was rated as moderate. No failure of efficacy was noted in any of the bleeding events. Thus overall out of 306 bleeding events, 295 (96.41%) showed excellent or good efficacy. Pharmacokinetic assessment based on plasma FVIII activity measured by the chromogenic assay in 12 patients showed comparative results similar to FVIII preparations. A total of 12 adverse events (AEs) were reported in this study. There was no inhibitor development in this previously treated patients (PTP) cohort. Conclusion: HemoRel-A® was established to be efficacious and safe in the treatment of acute bleeding events in subjects with severe hemophilia A.
Text
JAPI0039_p72_75
- Version of Record
More information
Accepted/In Press date: 13 April 2022
Published date: 1 July 2022
Additional Information:
Publisher Copyright:
© The Author(s).
Identifiers
Local EPrints ID: 470307
URI: http://eprints.soton.ac.uk/id/eprint/470307
ISSN: 0004-5772
PURE UUID: 2fc66ed5-c6ff-4195-ae61-ca1531d94dc5
Catalogue record
Date deposited: 06 Oct 2022 16:30
Last modified: 06 Jun 2024 02:08
Export record
Altmetrics
Contributors
Author:
Mayur Mewada
Author:
Subhaprakash Sanyal
Author:
Prasad Apsangikar
Author:
Ajay Kumar Yadav
Author:
Manoj Naik
Author:
Santosh Nair
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics